Physiomics plc

Physiomics specialises in integrating Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics with disease biology expertise to help biotech and pharma companies streamline drug development. Our goal is to extract actionable insights from all relevant data to de-risk critical decisions across discovery, preclinical, and clinical stages. This includes the optimal design of preclinical and clinical studies to give your drug the best chance of success. We leverage cutting-edge computational tools, custom-built models, and our proprietary Virtual Tumour technology to provide tailored solutions that accelerate development and optimise outcomes for our clients. With a track record of supporting over 100 commercial projects and modelling more than 125 targets and drugs, Physiomics has become a trusted partner to industry leaders such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.